Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTX-BP Trial: Rituximab (IDEC-C2B8) in steroid-resistant bullous pemphigoid
jRCT2031240107Phase 3Recruiting
- Sponsor
- Nippon Zenyaku Kogyo Co., Ltd.
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in Bullous Pemphigoid (BP) (4 arms), sponsored by Nippon Zenyaku Kogyo Co., Ltd. Primary endpoint: Maintenance of remission at 24 weeks. Started Aug 2024; status: recruiting.
02
Drugs
rituximab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on jRCT2031240107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240107.